Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary: To support the Regulatory Approval process of Metalyse® in Russian Federation.
Secondary: To assess the efficacy and safety of single bolus of Metalyse® TNK-tissue
plasminogen activator (TNK-tPA, Tenecteplase ) in patients with acute myocardial infarction
in usual routine treatment after market launch